Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

‘Nanobodies’ herald a new era in cancer therapy

12.05.2004


Cancer, along with heart and vascular disease, is the major cause of death in the Western world. The first generation of anti-cancer drugs has already saved many lives, but because these medicines are non-specific they also often have severe side effects. Researchers at VIB (the Flanders Interuniversity Institute for Biotechnology) are now developing ‘nanobodies’ − a new generation of drugs consisting of extremely small antibodies that target tumour cells very specifically.



The vast majority of the current medicines for treating tumours − the so-called chemotherapeutics − are seldom specific. Indeed, because a chemotherapy treatment is not only toxic to cancer cells but to the body’s normal cells as well, patients often experience severe side effects. The VIB research team under the direction of Hilde Revets and Patrick De Baetselier (Department of Molecular and Cellular Interactions, Free University of Brussels) is searching − successfully − for new, specific, effective cancer therapies.

For several years now, the leading strategy in the treatment of cancer has been based on the production of antibodies, which are protective substances produced in the organism to defend against intruding foreign bodies − protecting us against infections arising from bacteria and viruses. Antibodies can also react with tumour-specific substances that appear only on the cancer cell membrane. These ingenious antibodies seek out and bind very specifically to the cancer cells. As a result, the tumour is removed in a highly targeted, specific manner. At the moment, ten such medicines are available to patients. But even though these antibody medicines are a good step in the right direction, there is clearly room for improvement. The antibodies that are being used are large proteins that have difficulty penetrating tumours. In addition, their complex structure makes large-scale production very difficult and expensive.


In order to cope with these problems, the VIB researchers are using camel antibodies. Extremely small compared to conventional antibodies, this unique class of antibodies has been renamed ‘nanobodies’. Having all the advantages of the conventional antibodies, nanobodies also have several more important characteristics: they are small and they keep their tumour-specific character. At the same time, they are very stable, soluble proteins that are much easier and less expensive to produce than conventional antibodies. So, researchers have recently begun to evaluate nanobodies as anti-cancer medicines. The first results look promising: in experiments conducted on mice, a tumour with a certain protein on its membrane was successfully counteracted through administration of a nanobody directed against this protein.

To translate these results into a possible application for humans, VIB is collaborating with Ablynx, a company established by VIB and GIMV in 2001 with the aim of marketing the nanobody technology. Today, Ablynx has already developed nanobodies against 16 different therapeutic targets that represent a wide range of diseases in humans. Two of these nanobodies are in the pre-clinical phase and, according to plan, will be ready to be clinically tested next year.

These recent results are a new step toward the development of medicines based on nanobodies. In addition to cancer, other life-threatening diseases − such as certain inflammatory diseases, or heart and vascular diseases − are possibly eligible for a medical treatment with nanobodies.

Ann Van Gysel | alfa
Further information:
http://www.vib.be/

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>